{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040762","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.806413+00:00","generated_at":"2026-06-08T03:39:28.836550+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Evofem Q3 revenue $5.1M (-20% YoY); op loss narrows 81%; debt restructured; generic threat removed","bullets":["Net product sales $5.1M in Q3 vs $6.4M YoY; selling and marketing expenses cut 75%.","Net income $66M ($15.34 basic) from debt extinguishment gain; operating loss improved to $3.6M from $18.7M.","Fourth Amendment to $25M notes: waived default, removed revenue covenant; repurchase possible for as low as $14M.","Generic drug maker withdrew ANDA; will not seek FDA approval until Evofem Phexxi patents expire (2033)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040762","json":"https://secwatch.observer/filing/0001493152-23-040762.json","markdown":"https://secwatch.observer/filing/0001493152-23-040762.md","text":"https://secwatch.observer/filing/0001493152-23-040762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223040762/0001493152-23-040762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223040762/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:39:28.836550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"290c0c028e9082f600d224a0f679da2377f6e015","claim":"Evofem Biosciences, Inc. reported third quarter ended September 30, 2023 results: revenue $5.1 million in net product sales, net income net income was $66.0 million, EPS $15.34 per basic and $0.10 per diluted share.","evidence_excerpt":"November 14, 2023 —Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include: ● $5.1 million in net product sales of Phexxi ® (lactic acid, citric acid and potassium bitartrate) for the third quarter of 2023 and $13.4 million year-to-date 2023. ○ More than 82% of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223040762/0001493152-23-040762-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$5.1 million in net product sales"},{"label":"Net income","value":"net income was $66.0 million"},{"label":"EPS","value":"$15.34 per basic and $0.10 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e647406fd75b7443525ffce05fa4d1ee322b08c9","claim":"Evofem Biosciences, Inc. reported financial results for three and nine months ended September 30, 2023.","evidence_excerpt":"On November 14, 2023, Evofem Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223040762/0001493152-23-040762-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}